Marc Stapley, serving as both Chief Executive Officer and a director at Veracyte, Inc. (NASDAQ:VCYT), has formally disclosed the disposition of 138,051 shares of the company’s common stock. The aggregate value of this transaction stands at approximately $6,919,585. The execution of these sales took place on June 4, 2026, and was facilitated through a Rule 10b5-1 trading plan that Stapley originally adopted on November 24, 2025. This structured approach to share disposition is designed to manage insider trading compliance while allowing for predetermined liquidity events.
The shares were liquidated at a weighted average price of $50.1234. Individual transaction prices within this block ranged from $50.00 to $50.52. The sale activity was directly preceded by the exercise of an equal quantity of stock options. These options had achieved full vesting status and were exercised at a specific acquisition price of $36.60 per share. The total acquisition value associated with these exercised options amounted to approximately $5,052,666. This sequence of events underscores the mechanical nature of the underlying equity compensation structure rather than a discretionary market timing decision.
The timing of Stapley’s share sale coincides with Veracyte trading near its 52-week high of $50.71. The stock has delivered an impressive 85% return over the past year, a performance metric that has prompted scrutiny regarding its current valuation status. According to InvestingPro analysis, the stock currently appears overvalued relative to its calculated Fair Value. Investors seeking deeper insights can access comprehensive analysis through the company’s Pro Research Report, one of 1,400+ available for US equities.
In a separate transaction, Stapley disposed of 9,012 shares of Veracyte common stock on June 2, 2026. These shares were valued at $47.80 per share and were sold specifically to satisfy tax withholding obligations related to the vesting of restricted stock units. This transaction, totaling approximately $430,773, does not represent a discretionary sale by the reporting person. Following these transactions, Marc Stapley directly holds 440,494 shares of Veracyte, Inc. common stock. An administrative correction was also noted in the filing, adjusting previously reported shares acquired under the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2025, from 529 shares to 382 shares.
Veracyte Inc. has been active in product deployment and clinical validation. The company announced its U.S. commercial launch of the Prosigna Breast Risk of Recurrence test for patients with early-stage hormone-receptor positive breast cancer, available for order starting June 8, 2026. The Prosigna test predicts recurrence risk and chemotherapy benefit, combining clinical factors with intrinsic subtypes and proliferation scores. Additionally, Veracyte’s TrueMRD Monitoring Test for muscle-invasive bladder cancer has received Medicare coverage and will be available for clinicians to order on June 1, 2026. This test aids in monitoring recurrence following definitive treatment.
Analyst activity surrounding Veracyte reflects a spectrum of valuation assessments. Wolfe Research initiated coverage on Veracyte with an Outperform rating and a price target of $55.00, assessing the company at multiples in line with its peers. Meanwhile, Needham raised its price target on Veracyte shares to $57 from $48, maintaining a Buy rating after positive OPTIMA trial results. Canaccord reiterated a Hold rating on the company, maintaining a $42.00 price target following clinical study presentations at the American Society of Clinical Oncology 2026 Annual Meeting. These developments reflect ongoing interest and analysis from the investment community regarding Veracyte’s recent activities and future potential.
Market data indicates the stock closed at 49.94, reflecting a +1.25 (+2.57%) movement. After-hours trading showed a slight decline to 49.82, down -0.12 (-0.24%). The stock's recent trajectory has been closely monitored by institutional investors evaluating the balance between clinical catalysts and valuation multiples.